Information regarding Akynzeo sales figures is not publicly available. DrugPatentWatch.com tracks patent and exclusivity data for pharmaceuticals, which can impact sales and market exclusivity. [1]
When does Akynzeo's patent exclusivity end?
Akynzeo's core patents are expected to expire in the coming years. For example, U.S. Patent No. 8,921,392, which relates to Akynzeo, is listed with an expiration date of December 17, 2028. [2] However, the landscape of drug patents and exclusivity can be complex, involving multiple patents and potential extensions or challenges.
How do patents affect Akynzeo's market?
Patents grant a period of market exclusivity, preventing generic or biosimilar versions of a drug from being marketed. Once these patents expire, other companies may be able to produce and sell generic versions of Akynzeo, which typically leads to a significant decrease in the drug's price and a shift in market dynamics. [3]
What is Akynzeo used for?
Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV). It contains netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist. [4] This dual mechanism of action targets different pathways involved in nausea and vomiting.
Who manufactures Akynzeo?
Akynzeo is manufactured by Eisai Co., Ltd. [4]
How does Akynzeo work?
Akynzeo functions by blocking the action of substance P at NK1 receptors in the brain and by blocking serotonin at 5-HT3 receptors. These receptors play key roles in the emetic reflex, the body's mechanism for vomiting. By inhibiting these receptors, Akynzeo helps to prevent both acute and delayed nausea and vomiting associated with chemotherapy. [4]
Are there alternatives to Akynzeo for CINV?
Several other medications are available to prevent CINV, including other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids. The choice of antiemetic depends on the patient's specific chemotherapy regimen, risk factors for CINV, and individual patient characteristics. [5]
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, constipation, and indigestion. [4] As with any medication, patients should discuss potential side effects with their healthcare provider.
Sources:
1. https://drugpatentwatch.com/
2. DrugPatentWatch.com, U.S. Patent No. 8,921,392.
3. DrugPatentWatch.com, Understanding Drug Patents and Exclusivity.
4. U.S. Food and Drug Administration. (2014). FDA approves Akynzeo (netupitant and palonosetron) capsules.
5. National Cancer Institute. (2023). Nausea and Vomiting: Prevention and Treatment.